November 2022, Vol 12, No 11

In a special symposium held during the European Society for Medical Oncology Congress 2022, experts discussed lessons learned in the diagnosis and treatment of patients with primary brain tumors and what is on the horizon. Read More ›

To be compliant and offer the best support to their patients, healthcare providers need to understand the provisions of the Final Rule as it pertains to creating, maintaining, and sharing patient health data, and the impact of this legislation on their practices. Read More ›

When patients do not have reliable transportation, they cannot receive care for their cancer. Rachel Marquez, BS, MPH, Regional Operations Leader, Galileo Health, New York City, was determined to change this and set up a thriving pilot transportation program at her cancer center, Cone Health. Read More ›

New results from the PATHFINDER clinical trial suggest that a multicancer early detection blood test can accurately identify the presence of cancer in apparently healthy people. Read More ›

One-year follow-up data from a phase 3 study found similar duration of response, time to progression (TTP), and survival rates with the biosimilar candidate CT-P16 compared with its reference drug, bevacizumab (Avastin), in the first-line treatment of patients with metastatic or recurrent nonsquamous non–small-cell lung cancer (NSCLC). Read More ›

The increased use of biosimilars within the US Oncology Network generated more than $6 million of savings in the Centers for Medicare & Medicaid Services’ Oncology Care Model (OCM) during the first half of 2020. Read More ›

Providers participating in the Centers for Medicare & Medicaid Services’ (CMS’) value-based payment (VBP) models may realize a reduction in financial risk via biosimilar substitution. Read More ›

On September 21, 2022, the Association for Accessible Medicines (AAM), the leading trade association for generic and biosimilar manufacturers, released its 2022 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar medicines. Read More ›

Navigating the health insurance landscape in the United States is confusing—and particularly so in light of the ever-changing expansions under the Affordable Care Act (ACA)—but understanding the many existing disparities in cancer-related care and coverage can help providers to offer the best care possible to their patients and to find solutions for those who might be getting left behind. Read More ›

The Cholangiocarcinoma Foundation hosts a patient registry, the International Cholangiocarcinoma Patient Registry (ICPR), that is a global database comprising patient medical histories and treatments for cholangiocarcinoma (CCA). Read More ›